Vedolizumab in the therapy of ulcerative colitis patients
Milan Lukáš Orcid.org 1
+ Affiliation
Summary
Vedolizumab is a monoclonal IgG1 antibody, which has been approved to use in clinical practice for ulcerative colitis patients in Europan Union a few months ago. There is a big expectation on availability of vedolizumab at the market in Czech Republic in these year. The clinical research named GEMINI I proved that vedolizumab is a very effective drug in patients with moderate to severe ulcerative colitis. The significant advantages of vedolizumab therapy is a high efficacy in those patients who failed to anti‑TNFα therapy, sustained response due to maintenance therapy with arising effect over time, a minimal drug’s immunogenicity and highly safety drug’s profile, which is caused by a high selectivity for gastrointestinal tract. There are some disadvantages or uncertainty which include slow antiinflammatory therapeutic response, restricted effect on extraintestinal manifestations.
Keywords
biologic therapy, ulcerative colitis, vedolizumab
To read this article in full, please register for free on this website.
Benefits for subscribers
Benefits for logged users
Literature
1. Bortlík M. Vedolizumab – nová antiintegrinová protilátka s vysokou gastrointestinální selektivitou. Gastroent Hepatol 2014; 68(6): 481– 484. doi: 10.14735/ amgh 2014481.
2. Raine T. Vedolizumab for inflammatory bowel disease: Changing the game, or more of the same? United European Gastroenterol J 2014; 2(5): 333– 344. doi: 10.1177/ 2050640614550672.
3. Feagan BG, Rutgeerts P, Sands BE et al.
Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 2013; 369(8): 699– 710. doi: 10.1056/
NEJMoa1215734.
4. Lukáš M. Biologická léčba idiopatických střevních zánětů. In: Pavelka K, Arenberger P, Lukáš M et al (eds). Biologická léčba zánětlivých autoimunitních onemocnění v revmatologii, dermatologii a gastroenterologii. Praha: Grada 2014.
5. Lukáš M. Současnost a budoucnost v léčbě ulcerózní kolitidy.Gastroent Hepatol 2013; 67(3): 212– 218.